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Summary Sulfated glycosaminoglycans (GAGs) are complex polysaccharides, which are cova-
lently bound to protein cores to form proteoglycans. They are mostly located at the cell surface
and in the extracellular matrix (ECM) where they regulate numerous biological processes. The
aim of our work is (i) to identify and characterize protein—GAG interactions occurring at the cell
surface and in the ECM, (ii) to study the assembly of multimolecular complexes formed at the
cell surface via protein—heparan sulfate interactions, (iii) to determine the roles of these com-
plexes in the ECM maturation and assembly, which are initiated in the pericellular matrix, and
in pathological situations such as angiogenesis and host—pathogen interactions, (iv) to build,
contextualize and analyze the corresponding protein—heparan sulfate interaction networks to
identify molecular connections between the physio-pathological processes mentioned above
and to select protein—GAG complexes specifically formed in a pathological situation and which
might be therapeutic targets.
© 2016 Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Please cite this article in press as: Ricard-Blum, S., Protein—gl
sulfate. Perspect. Sci. (2016), http://dx.doi.org/10.1016/j.pis
 This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the
original author and source are credited. This article is part of a spe-
cial issue entitled Proceedings of the Beilstein Glyco-Bioinformatics
Symposium 2015 with copyright© 2017 Beilstein-lnstitut. Published
by Elsevier GmbH. All rights reserved.
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he extracellular matrix (ECM) is comprised of
74 core matrisome proteins and 747 matrisome-
ssociated proteins in humans (Naba et al., 2012,
ttp://matrisomeproject.mit.edu/). Most core matri-
ome proteins such as collagens, proteoglycans, elastin,
bronectin and laminins are multidomain proteins depositedycosaminoglycan interaction networks: Focus on heparan
c.2016.10.004
nder an insoluble form in the ECM and forming supramolec-
lar assemblies. Matrisome-associated proteins include ECM
egulators (degrading and cross-linking enzymes), secreted
an open access article under the CC BY license
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rowth factors and cytokines (e.g., TGF-) and ECM-
ffiliated proteins such as galectins. In addition to proteins,
he ECM contains linear, anionic, sulfated polysaccharides,
he glycosaminoglycans (GAGs), which are covalently
inked to proteins to form proteoglycans. The structural
nd functional roles of ECM are mediated by networks
f protein—protein and protein—GAG interactions, which
re constantly rewired according to the physiological and
athological contexts. We focus here on protein—GAG inter-
ctions and mostly on protein—heparin/heparan sulfate
nteractions involved in ECM assembly, angiogenesis and
nfectious diseases. Our goal is to decipher the molecular
echanisms underlying the above physiopathological pro-
esses and to identify protein—GAG complexes specific of a
articular disease as new potential therapeutic targets.
There are six glycosaminoglycans in mammals. Five of
hem (heparin, heparan sulfate, chondroitin sulfate, der-
atan sulfate and keratan sulfate) are sulfated and are
ovalently linked to proteins to form proteoglycans, whereas
yaluronan is not sulfated and forms aggregates of pro-
eoglycans by interacting non covalently with individual
roteoglycan molecules through link proteins. Proteogly-
ans are a large and heterogeneous family of forty-three
embers (Iozzo and Schaefer, 2015). They consist in one or
umerous glycosaminoglycan chains, which are covalently
inked to a core protein. Proteoglycans differ in the nature
f their protein core and in the nature and number of GAG
hains covalently linked to the protein core. Aggrecan com-
rises up to one hundred GAG chains whereas decorin bears
single GAG chain. Several proteoglycans bear two types of
AG chains and the type, number and size of GAG chains may
ary for a single proteoglycan depending on tissues (e.g.,
idney versus intestinal mucosa), cells and the biological
ontext (e.g., quiescent versus activated cells).
Heparin is widely used as a model of heparan sulfate for
n vitro studies. Both GAGs differ in the extent of sulfa-
ion and uronic acid epimerization. Heparin is more sulfated
1.8/2.6 sulfate/hexosamine ratio) than heparan sulfate
0.8—1.8 sulfate/hexosamine ratio) and contains a higher
mount of iduronic acid (70% versus 30—50% for heparan
ulfate) (Esko et al., 2009). Heparan sulfate has several
ost-synthetic modifications (N-, 2-O, 3-O, 6-O sulfation, N-
cetylation, glucuronic acid epimerization), which lead to
orty-eight possible disaccharides. Twenty-three disaccha-
ides have been identified so far in mammals for heparan
ulfate (Bülow and Hobert, 2006) which provide a huge struc-
ural heterogeneity to an heparan sulfate chain containing
p to 150 disaccharides. The sulfation is not homogeneous
long the heparan sulfate chain. There are regions of low —
r no — sulfation, called N-acetylated regions (NA), highly
ulfated regions (NS) and regions of intermediate sulfation
alled NA/NS. The NS domains and the intermediate domains
re the hypervariable regions that result in different func-
ional characteristics for heparan sulfate from different cell
ypes and tissues. In addition, a further post-synthetic mod-
fication of heparan sulfate occurs at the cell surface, where
xtracellular endosulfatases, called Sulfs, catalyze the spe-
ific removal of 6-O sulfate groups (Vivès et al., 2014).Please cite this article in press as: Ricard-Blum, S., Protein—g
sulfate. Perspect. Sci. (2016), http://dx.doi.org/10.1016/j.pis
The structural heterogeneity of heparan sulfate chains
ranslates into functional diversity. Indeed, heparan sulfate
hains fulfill a variety of biological roles. They are involved
n ECM assembly, cell-ECM interactions, cell adhesion,
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igration and proliferation by interacting with recep-
ors such as integrins (Faye et al., 2009a), growth factor
equestration within the ECM, development, angiogenesis,
ancer, neurodegenerative diseases (interaction with the
-amyloid peptide), host-pathogen interactions and innate
mmunity. The goal of our work is to translate heparan
ulfate—protein interactions into functions to decipher the
olecular mechanisms of action of heparan sulfate, to
dentify new therapeutic targets and ultimately to design
mall molecules inhibiting specific protein—GAG interac-
ions based on structural and molecular features both on
rotein and GAG involved in the formation of the complex.
argeting molecular interactions with small molecules is one
f the approaches used in pharmacology (Jin et al., 2014).
roadmap to build, contextualize and analyze
rotein—GAG interaction networks
e have designed a roadmap to build, contextualize, and
nalyze extracellular protein—protein and protein—GAG
nteraction networks (Fig. 1) including the following steps:
1) identification of new interactions by surface plasmon res-
nance (SPR) and SPR imaging (SPRi) using ECM protein and
AG arrays we have developed (Faye et al., 2009b; Fatoux-
rdore et al., 2014; Salza et al., 2014), (2) collection of fur-
her interaction data by manual curation of the literature,
3) storage of interaction data in MatrixDB, the interaction
atabase we have developed (http://matrixdb.ibcp.fr/,
hautard et al., 2009, 2011; Launay et al., 2015; cf.
elow), (4) querying MatrixDB and other interaction
atabases to build comprehensive interaction networks
f a molecule (GAG or protein), (5) contextualization of
he network by adding kinetics and affinity of interac-
ions calculated by SPR, quantitative proteomic data when
vailable, Gene Ontology terms (http://geneontology.org/,
ene Ontology Consortium, 2015), annotations from the
eactome pathway database (http://www.reactome.org/,
roft et al., 2014) and the Kyoto Encyclopedia of
enes and Genomes (KEGG, http://www.genome.jp/kegg/,
anehisa et al., 2015), and expression data from UniGene
http://www.ncbi.nlm.nih.gov/unigene, Pontius et al.,
003). The integration of the above data into the networks
llows the building in MatrixDB of networks specific of a tis-
ue, a biological process, a molecular function, a pathway
r a disease. The networks are visualized using the iNavi-
ator of MatrixDB (Launay et al., 2015) and/or Cytoscape,
‘an open source software platform for visualizing molecular
nteraction networks and biological pathways and inte-
rating these networks with annotations, gene expression
rofiles and other state data’’ (http://www.cytoscape.org/,
u et al., 2014). Enrichment analyses restricted so far to
he proteins of the networks are performed with Cytoscape
pps and the Functional Enrichment analysis tool FunRich
http://www.funrich.org/, Pathan et al., 2015).
Most tools that are currently available to analyze
olecular interaction networks and to perform enrich-
ent analyses have been designed for protein—proteinlycosaminoglycan interaction networks: Focus on heparan
c.2016.10.004
nteraction networks and are thus useless for protein—GAG
nteraction networks or for networks comprising both
rotein—protein and protein—GAG interactions. However,
n enrichment analysis tool based on the ChEBI (Chem-
ARTICLE IN PRESS+ModelPISC-387; No. of Pages 8
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Figure 1 Roadmap to build extracellular and pericellular protein—GAG interaction networks. The heparin—heparan sulfate inter-
action network comprises 150 and 52 partners (in blue) for heparin and heparan sulfate (in red) respectively. Diamonds: multimeric
proteins (e.g., collagens, laminins), Crosses: protein fragments (e.g., endostatin, a fragment of collagen XVIII), Squares: proteins.
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Genomes, SPR: surface Plasmon Resonance).
ical Entities of Biological Interest) ontology and called
BiNChE has been recently developed for small molecules
including glycosaminoglycan constitutive disaccharides
(http://www.ebi.ac.uk/chebi/tools/binche/, Moreno
et al., 2015). It has been integrated into the Gene Ontology
resource (Hill et al., 2013) and we will use BiNChE for future
analyses of protein—GAG interactomes.
Identification of protein—GAG and
pathogen—GAG interactions by SPR imaging
(SPRi)
SPR binding assays are performed in real time and do
not require labeling of the interactants. One interactant
is immobilized on a gold surface and its potential part-
ner is injected in solution at various flow rates over the
immobilized interactant. The binding is detected by surface
plasmon resonance, which is an optical phenomenon. SPRi
binding assays are carried out in a Biacore Flexchip instru-
ment to identify new protein—GAG interactions, whereas
classical SPR experiments are performed in a Biacore T100
instrument to calculate kinetic parameters and affinity of
newly identified protein—GAG interactions. Both Biacore
systems we use are from GE Healthcare and belong to the
Protein Science Facility of UMS 3444/US 8 (Lyon, France).
New protein—glycosaminoglycan interactions are iden-
tified by SPRi with protein and glycosaminoglycan arraysPlease cite this article in press as: Ricard-Blum, S., Protein—gl
sulfate. Perspect. Sci. (2016), http://dx.doi.org/10.1016/j.pis
comprised of about one hundred molecules (proteins and
GAGs) spotted in triplicate on Gold affinity chips (GE Health-
care). GAGs are spotted (1mg/ml) either as bound to a
protein core under a proteoglycan form when available or
wMatrixDB database. (KEGG: Kyoto Encyclopedia of Genes and
s free GAG chains from several species (heparan sulfate
rom bovine kidney and from intestinal mucosa) and/or of
igh- and low-molecular weight (heparin and hyaluronan).
roteoglycans and GAGs are physically adsorbed onto the
are gold surface without any chemical reaction. Purified
roteins (Faye et al., 2009b; Salza et al., 2014) or intact
athogens (Leishmania parasites, Fatoux-Ardore et al.,
014) are injected at a flow rate of 300—500  l/min (pro-
eins) or 150  l/min (pathogens) and recirculated over the
potted GAGs for 25min (proteins) or 2 h (pathogens). Using
his approach we have shown that 83.5 and 62.5% of the 24
trains of Leishmania parasites we have tested bind to hep-
rin and heparan sulfate, respectively, whereas only 8.3%
he 24 strains of Leishmania interact with chondroitin or
ermatan sulfate (Fatoux-Ardore et al., 2014).The role of
ulfate groups in the binding of proteins or pathogens to
eparin is investigated by spotting selectively desulfated
eparins (Iduron, UK) on the arrays. We have shown that 6-
-sulfate groups of heparin play a crucial role in its binding
o Leishmania parasites (Fatoux-Ardore et al., 2014).
Several Leishmania strains interact with heparin but not
ith heparan sulfate. This might be due to differences in the
tructures of these GAGs. Heparan sulfate is less sulfated
han heparin, contains clustered sulfate groups organized in
ighly sulfated domains, is more flexible and has a longer and
ore bent structure than heparin (Khan et al., 2013). Hep-
ran sulfate may thus interact differently with pathogens
r proteins compared with heparin. It is thus not correct to
utomatically infer that pathogens or proteins interactingycosaminoglycan interaction networks: Focus on heparan
c.2016.10.004
ith heparin also bind to heparan sulfate.
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anual curation of the literature: storage of
rotein—GAG interaction data in MatrixDB, a
atabase focused on ECM interactions
o collect protein—GAG interaction data from the lit-
rature we have built a molecular interaction database
alled MatrixDB (http://matrixdb.ibcp.fr/, Chautard et al.,
009, 2011; Launay et al., 2015) focused on interac-
ions involving at least one extracellular matrix protein
nd/or one glycosaminoglycan. MatrixDB was the first
nteraction database and is currently the only one to sys-
ematically curate protein—GAG interaction data. MatrixDB
elongs to the International Molecular Exchange consor-
ium (IMEx, http://www.imexconsortium.org/) and follows
he IMEx curation rules (Orchard et al., 2012). MatrixDB
erforms curation of the papers published in Matrix
iology and of other papers related to ECM assem-
ly, ECM maturation, angiogenesis and infectious diseases
hrough the curation platform developed by the IntAct
atabase and currently used by eleven interaction databases
http://www.ebi.ac.uk/intact/, Orchard et al., 2014).
rotein—protein and protein—GAG interaction data curated
y MatrixDB are freely available on our website, where they
an be downloaded under a tabular format and/or as inter-
ction networks built with the iNavigator we developed
Launay et al., 2015). Furthermore MatrixDB has imple-
ented a Proteomics Standard Initiative Common Query
nterfaCe (PSICQUIC) for computational access to molecular
nteraction data resources (Aranda et al., 2011). The query
f a single database having implemented PSICQUIC returns
he interaction data stored in other interaction databases
aving also implemented the PSICQUIC service.
One of the first issues to address for the curation of
rotein—GAG interactions was to select an identifier for
lycosaminoglycans. In agreement with the IMEx curation
ules we have selected the identifiers of the Chemical Enti-
ies of Biological Interest for glycosaminoglycans (ChEBI,
ttp://www.ebi.ac.uk/chebi/init.do, Hastings et al., 2013)
ased on their constitutive disaccharides. This identifier
oes not take into account the structural diversity of the
isaccharides of GAGs described above but neither PubChem
dentifier (Kim et al., 2016), nor the IUPAC International
hemical Identifier for chemical substances (InChITM, Heller
t al., 2013, 2015) do it.
n vitro and in silico localization of binding
ites for protein—GAG interactions
he role of sulfate groups in the binding of GAGs to proteins
s deciphered by SPRi as described above or by SPR using
nhibition experiments. In this case, proteins are preincu-
ated with selectively desulfated heparins before injection
ver immobilized heparin. We have shown that N-sulfate and
-O sulfate groups of heparin strongly contribute to its bind-
ng to a fragment of collagen V (HepV, Ricard-Blum et al.,
006) and of collagen XVIII (endostatin, Ricard-Blum et al.,Please cite this article in press as: Ricard-Blum, S., Protein—g
sulfate. Perspect. Sci. (2016), http://dx.doi.org/10.1016/j.pis
004), respectively. Inhibition experiments are also carried
ut with heparin and heparan sulfate oligosaccharides (from
etrasaccharides to octadecasaccharides) to determine the
inimum size of heparin or heparan sulfate required to
p
o
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romote an efficient binding to proteins. An octasaccha-
ide of heparin is sufficient to promote the binding of the
ctodomain of  51 integrin (Faye et al., 2009a), whereas
decasaccharide and an hexadecasaccharide of heparan
ulfate are required to bind a fragment of collagen V (Ricard-
lum et al., 2006) and collagen XVIII (Ricard-Blum et al.,
004), respectively.
We have used the AutoDock program and molecular
ynamic simulations to localize the binding site(s) of hep-
rin on the 3D structure of endostatin (Ricard-Blum et al.,
004) and of the ectodomain of the  v3 integrin (Ballut
t al., 2013) by molecular modeling. We have identified two
urther arginine residues of endostatin (Arg47 and Arg66) con-
ributing to its interaction with heparin (Ricard-Blum et al.,
004) and we have shown that heparan sulfate could bind
o different sites on RGD-dependent and RGD-independent
ntegrins (Ballut et al., 2013).
The chemical groups and features of GAGs contribut-
ng to their binding to proteins or pathogens (e.g., sulfate
roups, size, and oligosaccharide sequences) are currently
tored in MatrixDB as free text, which restricts searches
ithin the database and data exchanges with other interac-
ion databases. A disaccharide code, based on a 4-character
escriptor (uronic acid, presence and location of sulfate
roups, hexosamine and the N-substituent, pattern of sul-
ation on the hexosamine) has been proposed for GAGs by
awrence et al. (2008) but it has not been widely adopted
y the GAG community. We will use in the future a uni-
ying sequence format for carbohydrates (GlycoCT, Herget
t al., 2008) and/or the Web3 unique representation of car-
ohydrate structures (WURCS, Tanaka et al., 2014), a linear
otation which can be used as a Uniform Resource Identifier,
o represent heparin/heparan sulfate features responsible
or protein or pathogen binding. These data are of crucial
mportance because the pattern of GAG post-synthetic mod-
fications (sulfation, acetylation, epimerization) and their
onformation modulate their molecular recognition, their
nteraction repertoire and hence their biological functions.
onformational changes occurring in proteins upon their
inding to heparin/heparan sulfate may be demonstrated by
ircular dichroism (CD). The comparison of CD spectra of a
ragment of collagen V in absence and in presence of heparin
r heparan sulfate has shown that no significant structural
hange is induced in this protein fragment upon GAG binding
Ricard-Blum et al., 2006).
inetics and affinity of
rotein—heparin/heparan sulfate interactions
inetic parameters (i.e., association and dissociation rates)
llow the discrimination of transient and stable interactions,
hereas the affinity, which characterizes to the strength
f the interaction, discriminates strong and weak interac-
ions and is useful to prioritize interactions within networks.
inetics and affinity of interactions are calculated by SPR
inding assays performed in a Biacore T100 system, which is
ore sensitive than the Biacore Flexchip used for screeninglycosaminoglycan interaction networks: Focus on heparan
c.2016.10.004
urpose. Biotinylated heparin or heparan sulfate is captured
nto streptavidin, which is covalently immobilized via its
mino groups onto a sensor chip functionalized with a car-
oxymethyl dextran layer (Ricard-Blum et al., 2004, 2006;
ARTICLE IN PRESS+ModelPISC-387; No. of Pages 8
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Table 1 Lifetime of the complexes formed by ECM proteins or fragments, secreted proteins and integrin with heparin and
heparan sulfate. The lifetime of the complexes was calculated as the reciprocal of the dissociation rate determined by SPR
binding assays. Two lifetimes were calculated for integrin—GAG interactions involving the formation of a first complex, which
rearranges in a more stable complex, and for angiopoietin-like-4, which comprises two binding sites for heparan sulfate. The
first value corresponds to the fixation of heparan sulfate on one binding site and the second value to the binding of heparan
sulfate on the second binding site.
Protein GAG Interaction model Complex lifetime
(1/kd, min)
Reference
Procollagen
C-Proteinase
Enhancer-1
Heparin 1:1 model  ∼44 Weiss et al. (2010)
Heparan sulfate 1:1 model  ∼37
Endostatin Heparin 1:1 model ∼4 Ricard-Blum et al.
(2004)Heparan sulfate <1
Transglutaminase-2 Heparin 1:1 model 34 Scarpellini et al. (2009)
51 integrin Heparin 2-state
(conformational
change)
<1
∼66
Faye et al. (2009a)
Heparan sulfate ∼1
∼31
Angiopoietin-like 4 Heparan sulfate Bivalent analyte
model (2 binding
sites for heparan
sulfate on the
∼2
∼73
Chomel et al. (2009)
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Weiss et al., 2010). Proteins are then injected at several
concentrations over captured GAGs. Each sensor chip has
four flow cells, the first one being a control flow cell used
to evaluate the non-specific binding of injected proteins
to the sensor chip surface. Kinetics and affinity are calcu-
lated using predetermined interaction models available in
the Biaevaluation software (GE Healthcare). The associa-
tion rate reflects themolecular recognition of both partners,
whereas the dissociation rate reflects the stability of the
complex resulting from the interaction of both partners. The
reciprocal of the dissociation rate (kd) is an evaluation of
the complex lifetime and consequently of the duration of
the biological effects triggered by the interaction. It allows
the comparison of the lifetime of complexes formed via dif-
ferent molecular mechanisms, reported in Table 1 as the
interaction model fitting the experimental interaction data.
The complexes formed by heparin/heparan sulfate with cell
surface-associated proteins have very different lifetimes,
ranging from 50 s to 70min (Table 1).
Relationship between kinetics, affinity
molecular and biological functions
We have built a dataset of 125 protein—heparin/heparan sul-
fate interactions for which affinity and kinetic parameters
are available in order to determine if there is a relationship
between the molecular functions of heparin-binding pro-
teins, their localization, the biological processes they arePlease cite this article in press as: Ricard-Blum, S., Protein—gl
sulfate. Perspect. Sci. (2016), http://dx.doi.org/10.1016/j.pis
involved in, and the affinity or kinetics of their interactions
with heparin/heparan sulfate. The dataset was comprised
of data stored in MatrixDB database and of data manually
curated from the literature (Peysselon and Ricard-Blum,
f
l
t
m014). Lipoproteins, growth factors and cytokines bind to
eparin with a higher affinity than proteins playing a role
n ECM assembly and organization. Enzymes interact with
eparin with a higher affinity than the other proteins and
orm more stable complexes with heparin than the other
roteins. In addition, heparin-binding proteins regulating
ngiogenesis have on average a higher affinity for heparin
han other proteins. The association rates were higher for
roteins regulating angiogenesis than for other proteins and
he complexes formed with heparin by proteins regulating
ngiogenesis dissociated faster than those formed by other
roteins (Peysselon and Ricard-Blum, 2014).
erspectives
urther experimental approaches are needed to address
he limitations of those currently used to characterize
rotein—heparan sulfate interactions and the correspond-
ng interaction networks. The vast majority of the studies
arried out so far to characterize protein—heparan sulfate
nteractions in physiopathological contexts are performed
ith commercially available heparan sulfate chains, which
ay differ by their post-synthetic modifications from those
resent in tissue(s) or at the surface of cell(s) involved
n the biological processes investigated. It would thus
e more appropriate to study protein—heparan sulfate
nteractions with heparan sulfate chains purified from tis-
ues and/or from cell surface to identify the molecularycosaminoglycan interaction networks: Focus on heparan
c.2016.10.004
eatures contributing to their binding to proteins in a bio-
ogically relevant context. Other parameters of interest
o take into account in order to delineate the molecular
echanisms underlying the biological effects triggered by
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rotein—heparan sulfate interactions in vivo are the follow-
ng:
i) The quantization of heparan sulfate at the cell surface
and/or in tissues to correctly use the affinity of these
interactions in prioritizing them in interaction networks.
This should be possible with the methods recently devel-
oped for quantitative glycomics (Staples and Zaia, 2011;
Mechref et al., 2013).
ii) The protein core presenting heparan sulfate, and other
GAGs, to their protein partners. The characterization
of protein—GAG interactions in vitro with free sulfated
GAG chains do not recapitulate the in vivo situation
since heparan sulfate chains are not free either in the
ECM or at the cell surface. Syndecan-glycosaminoglycan
intramolecular cross-talk matters for protein—heparan
sulfate interactions in different cellular microenviron-
ments. Indeed the number, size and types of GAG
chains covalently linked to the four membrane proteo-
glycans syndecans vary according to the cell type and/or
activation, which leads to the continuous rewiring of
the interaction repertoires depending on the biological
context (Eriksson and Spillmann, 2012). Binding assays
performed with proteoglycans, in addition to those per-
formed with free GAGs, will be useful to discriminate
interactions involving the protein core of proteoglycans
from those involving their GAG chain(s), and to refine
the proteoglycan interaction network. The current draft
of this network comprises 30 proteoglycans (73% of the
known proteoglycans), 179 partners and 557 biomolecu-
lar interactions (Peysselon et al., 2012).
ii) The crowding at the cell surface, which is covered by a
layer called glycocalyx, which is enriched in proteogly-
cans and GAGs. The endothelial cell surface for instance
is highly crowded with numerous heparan and chon-
droitin sulfate chains linked to syndecans and glypicans
and hyaluronan, a non-sulfated GAG. The composi-
tion and thickness of the glycocalyx vary, depending
on cell type. The migration of ECM proteins or pro-
tein fragments (e.g., endostatin) through this intricate
3D network enriched in GAGs to reach their specific
cell-surface receptors such as integrins buried into the
glycocalyx warrants further investigation. Heparan sul-
fate likely plays a role in this process as shown for the
transport of fibroblast growth factor 2 in the pericellu-
lar matrix, which is controlled by the spatial distribution
of its binding sites in heparan sulfate (Duchesne et al.,
2012).
v) The role of membrane lipids in the organization and
distribution of syndecans, glypicans and part-time mem-
brane or membrane-associated proteoglycans within the
plasma membrane.
Another concern is to cross-reference MatrixDB
ith other glycan databases to improve exchanges of
rotein—GAG interaction data, not only with the IMEx
nteraction databases, which is already done, but also
ith other glycan databases such as Glyco3D, a portalPlease cite this article in press as: Ricard-Blum, S., Protein—g
sulfate. Perspect. Sci. (2016), http://dx.doi.org/10.1016/j.pis
or structural glycosciences providing the 3D features of
onosaccharides, oligosaccharides, polysaccharides, and
AG-binding proteins (http://glyco3d.cermav.cnrs.fr, Pérez
t al., 2015), and SugarBind, which provides information
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